An overview of Psoriasis: literature review

Article Sidebar

PDF (Português (Brasil))
Published Nov 4, 2022
DOI https://doi.org/10.25248/reamed.e11125.2022

Main Article Content

Juliana Peres Pimentel
Universidade de Vassouras
Rafaella de Almeida Vieira
Universidade de Vassouras
Gabriella de Almeida Vieira
Universidade de Vassouras
Bruna Simões Lacerda
Universidade de Vassouras
Raquel do Nascimento Almeida
Universidade de Vassouras
Laura Certório Campos Lisboa
Universidade de Vassouras
Emílio Conceição de Siqueira
Universidade de Vassouras

Abstract

Objective: To analyze the characteristics of Psoriasis. Bibliographic review: Psoriasis is a chronic, immune-mediated systemic disease that affects approximately 100 million people worldwide. The disease appears to be the result of a dysregulated interaction between immune cells, skin keratinocytes and the environment, leading to a persistent inflammatory process modulated by activated T cells and pro-inflammatory cytokines. Psoriasis is associated with an increased risk of comorbidities, including, but not limited to, psoriatic arthritis, cardiovascular disease, diabetes mellitus, obesity, inflammatory bowel disease, and nonalcoholic fatty liver disease compared to the general population. Final considerations: Psoriasis is a global public health problem, being a chronic systemic inflammatory skin disease with strong genetic predisposition and autoimmune pathogenic traits. Its treatment in mild cases is performed with topical agents such as Calcipotriol, Calcineurin Inhibitors, Tretinoin, glucocorticoid and phototherapy. In moderate to severe cases, conventional systemic therapies such as Methorexate, Cyclosporine and Acitretin are used, in addition to biologicals that can be used in the failure of conventional therapies.

Article Details

How to Cite
PimentelJ. P., VieiraR. de A., VieiraG. de A., LacerdaB. S., AlmeidaR. do N., LisboaL. C. C., & SiqueiraE. C. de. (2022). An overview of Psoriasis: literature review. Revista Eletrônica Acervo Médico, 20, e11125. https://doi.org/10.25248/reamed.e11125.2022
Issue
Vol 20 (2022): Revista Eletrônica Acervo Médico (ISSN 2764-0485) | Volume 20 | 2022
Section
Revisão Bibliográfica

Copyright © | All rights reserved.

The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.

Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.

Total reproduction
It is expressly prohibited and must be authorized by the journal.

References

1. BOEHNCKE WH. Systemic Inflammation and Cardiovascular Comorbidity in Psoriasis Patients: Causes and Consequences. Front Immunol, 2018; 9: 579.

2. DAND N, et al. Psoriasis and Genetics. Acta Derm Venereol, 2020; 100(3): adv00030.

3. DOPYTALSKA K, et al. The Role of Epigenetic Factors in Psoriasis. Int J Mol Sci, 2021; 22(17): 9294.

4. FERRELI C, et al. Histopathological aspects of psoriasis and its uncommon variants. G Ital Dermatol Venereol, 2018; 153(2): 173-184.

5. FU Y, et al. Association of Psoriasis With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. JAMA Dermatol, 2018; 154(12): 1417-1423.

6. GIROLOMONI G, et al. The role of IL-23 and the IL-23/TH 17 immune axis in the pathogenesis and treatment of psoriasis. J Eur Acad Dermatol Venereol, 2017; 31(10): 1616-1626.

7. GRAN F, et al. Current Developments in the Immunology of Psoriasis. Yale J Biol Med, 2020; 93(1): 97-110.
8. KAMATA M e TADA Y. Efficacy and Safety of Biologics for Psoriasis and Psoriatic Arthritis and Their Impact on Comorbidities: A Literature Review. Int J Mol Sci, 2020; 21(5): 1690.

9. KAMIYA K, et al. Risk Factors for the Development of Psoriasis. Int J Mol Sci, 2019; 20(18): 4347.

10. KORMAN NJ. Management of psoriasis as a systemic disease: what is the evidence? Br J Dermatol, 2020; 182(4): 840-848.

11. MASSON W, et al. Psoriasis and Cardiovascular Risk: A Comprehensive Review. Adv Ther, 2020; 37(5): 2017-2033.

12. MEROLA JF, et al. Underdiagnosed and undertreated psoriasis: Nuances of treating psoriasis affecting the scalp, face, intertriginous areas, genitals, hands, feet, and nails. Dermatol Ther, 2018; 31(3): e12589.

13. OGAWA K e OKADA Y. The current landscape of psoriasis genetics in 2020. J Dermatol Sci, 2020; 99(1): 2-8.

14. OLEJNICZAK-STARUCH I, et al. Alterations of the Skin and Gut Microbiome in Psoriasis and Psoriatic Arthritis. Int J Mol Sci, 2021; 22(8): 3998.

15. OSMANCEVIC A e STAHLE M. Treatment of psoriasis: before and now. Lakartidningen, 2017; 114: EU6Y.

16. PETIT RG, et al. Psoriasis: From Pathogenesis to Pharmacological and Nano-Technological-Based Therapeutics. Int J Mol Sci, 2021; 22(9): 4983.

17. REID C e GRIFIFITHS CEM. Psoriasis and Treatment: Past, Present and Future Aspects. Acta Derm Venereol, 2020; 100(3): adv00032.

18. RENDON A e SCHAKEL K. Psoriasis Pathogenesis and Treatment. Int J Mol Sci. 2019; 20(6): 1475.

19. RONHOLT K e IVERSEN L. Old and New Biological Therapies for Psoriasis. Int J Mol Sci, 2017; 18(11): 2297.

20. ROSZKIEWICZ M, et al. Environmental risk factors and epigenetic alternations in psoriasis. Ann Agric Environ Med, 2020; 27(3): 335-342.

21. SINGH R, et al. The Cytokine Mediated Molecular Pathophysiology of Psoriasis and Its Clinical Implications. Int J Mol Sci, 2021; 22(23): 12793.

22. SU W, et al. Exploring the Pathogenesis of Psoriasis Complicated With Atherosclerosis via Microarray Data Analysis. Front Immunol, 2021; 12: 667690.

23. TOKUYAMA M e MABUCHI T. New Treatment Addressing the Pathogenesis of Psoriasis. Int J Mol Sci, 2020; 21(20): 7488.

24. YANG K, et al. Use of IL-23 Inhibitors for the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review. Am J Clin Dermatol, 2021; 22(2): 173-192.

25. ZHANG P e WU MX. A clinical review of phototherapy for psoriasis. Lasers Med Sci, 2018; 33(1): 173-180.